Differences in and verification of genetic alterations in chemotherapy and immunotherapy for metastatic melanoma.

ABSTRACT:

Background

Metastatic melanoma has poor therapeutic response and may present resistance to chemotherapy or immunotherapy. Significant differences are observed in the survival time of patients with metastatic melanoma based on the administration of chemotherapy or immunotherapy; thus, we have explored the important role of specific differential genes between the two therapies in their effect on treatment response in melanoma.

Methods

Metastatic melanoma gene expression data (RNAseq, mutation and methylation) and patient clinical information were downloaded from The Cancer Genome Atlas database and grouped according to chemotherapy or immunotherapy. The differentially expressed genes of the two groups were further screened for signature genes through a protein-protein interact

SUBMITTER: Li Y 

PROVIDER: S-EPMC8580330 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature